Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)

Trial Profile

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Realm Therapeutics
  • Most Recent Events

    • 12 Mar 2018 Status changed from recruiting to discontinued, According to a Realm Therapeutics media release.
    • 15 Feb 2018 According to a Realm Therapeutics media release, study is ahead of schedule with top-line results expected by the end of Q1 2018, rather than in Q2 as previously indicated.
    • 12 Dec 2017 Status changed from planning to recruiting, according to a Realm Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top